• Balsalazide in Active Ulcerative Colitis: 2009 Review

  2026-09-11

  The 2009 review by Wiggins and Rajapakse examined balsalazide as a colon-targeted 5-aminosalicylate prodrug, emphasizing bacterial azoreduction and localized 5-aminosalicylic acid release. Its clinical synthesis indicated effective remission induction in mild-to-moderate active ulcerative colitis, with faster symptomatic improvement and a safety profile comparable to other oral 5-ASA agents.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-11

  The reference study identifies CD44 as a metabolic dependency of IDH-mutant leukemia rather than only an adhesion marker. Its data connect CD44-driven activation of the pentose phosphate pathway and suppression of glycolysis to NADPH supply, R-2HG production, and a potential combination strategy with mutant-IDH inhibition.

• LGK-974: Precision PORCN Inhibitor Workflow

  2026-09-10

  LGK-974 enables selective, upstream suppression of Wnt ligand secretion for pathway validation, biomarker studies, and Wnt-dependent cancer models. This guide connects practical cell-culture workflows with developmental Wnt biology while emphasizing formulation, controls, and interpretation.

• Balsalazide disodium: UC Research Workflows

  2026-09-10

  Explore practical workflows for using Balsalazide disodium in inflammation research, azoreductase-aware assays, and ulcerative colitis imaging studies. The guide connects solution preparation and radioiodination parameters with controls, troubleshooting, and translational limitations.

• Doxorubicin in 3D Collagen Cancer Models

  2026-09-09

  Use Doxorubicin as a mechanistically anchored chemotherapy control in collagen microtissues that reproduce hypoxia, stemness, and treatment resistance more realistically than many monolayers. This workflow connects dose design, matrix-aware exposure, and orthogonal apoptosis readouts for solid-tumor and hematologic malignancy research.

• ω-Agatoxin IVA in Epileptogenesis: Study Insights

  2026-09-09

  This rat study identifies selective P/Q-type calcium-channel blockade by ω-agatoxin IVA as a way to suppress chemical kindling while preserving motor coordination. Its combination of EEG, behavioral testing, and BDNF/cleaved caspase-3 immunohistochemistry links seizure control with neurotrophic and apoptosis-related changes, although translation beyond the experimental model remains uncertain.

• Monomethyl Auristatin E: A State-Aware ADC Assay

  2026-09-08

  Monomethyl auristatin E (MMAE) is more than a potent ADC payload: it can serve as a functional probe of microtubule dependence, intracellular delivery, and tumor-cell state. This article connects MMAE assay design with the epigenetic plasticity framework established in nasopharyngeal carcinoma while separating evidence from hypothesis.

• DPP9–KEAP1 Redox Control of Inflammasome Signaling

  2026-09-08

  The reference study identifies KEAP1 as an endogenous binding partner that captures DPP9 in an inactive, non-native conformation, revealing a direct connection between redox sensing and DPP9 regulation. It also shows reciprocal inhibition: DPP9-bound KEAP1 is less able to engage NRF2, producing an antioxidant response and establishing a mechanistic framework for studying redox-linked inflammasome control.

• Balsalazide Disodium Dihydrate in Cell Assays

  2026-09-07

  This scenario-based guide explains how Balsalazide Disodium Dihydrate, SKU C6459, can be incorporated into viability, proliferation, cytotoxicity, and inflammatory bowel disease model workflows. It emphasizes activation biology, solvent controls, dose translation, interpretation limits, and practical product-selection criteria supported by product data and peer-reviewed literature.

• Reserpine (N1867): Practical Lab Workflow

  2026-09-07

  Reserpine (N1867) provides a defined research reagent for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and troubleshooting; the material is for research use only and is not intended for diagnostic, clinical, therapeutic, or veterinary applications.

• GS-441524 Workflow for Antiviral Research

  2026-09-05

  Build more informative antiviral and pharmacokinetic studies by pairing GS-441524 exposure measurements with conversion-pathway analysis. This practical workflow addresses DMSO formulation, matrix handling, LC–MS/MS sampling, cell-based interpretation, and common troubleshooting points.

• DiscoveryProbe FDA-approved Drug Library for Thymic Screens

  2026-09-04

  Learn how to use the DiscoveryProbe FDA-approved Drug Library to identify compounds that restore thymic epithelial cell function, using Foxn1 induction as a practical screening endpoint. The workflow combines phenotypic screening, viability gating, mechanistic follow-up, and orthogonal validation for drug repositioning screening and pharmacological target identification.

• Mitochondrial Signaling in Bladder Cancer

  2026-09-04

  A translational perspective on how LRG1-driven neutrophil mitochondrial disruption may contribute to pathological angiogenesis in bladder cancer, and how ratiometric JC-1 analysis can strengthen mechanistic validation without overstating what ΔΨm alone can prove.

• Red Blood Cell Lysis Buffer: K1169 Guide

  2026-09-03

  Red Blood Cell Lysis Buffer K1169 uses ammonium chloride to selectively lyse mammalian erythrocytes while retaining lymphocytes and other nucleated cells. It supports blood sample preparation for flow cytometry, nucleic acid extraction, protein extraction, and cell culture, but it is not suitable for birds or poultry.

• Praeruptorin A: Applied Research Workflows

  2026-09-03

  Praeruptorin A connects Fe²⁺-focused ferroptosis assays with inflammation, epithelial-barrier, metastasis, and cardiomyopathy research. This practical guide translates its multi-target profile into reproducible workflows, decision points, and troubleshooting strategies for cell and animal studies.

8038 records 1/536 page Next 12345 下5页 Last page